ELOVL3

Summary

ELOVL3 (ELOVL fatty acid elongase 3, HGNC:18047) is a protein-coding gene on chromosome 10q24.32, encoding Very long chain fatty acid elongase 3 (Q9HB03). Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle.

This gene encodes a protein that belongs to the GNS1/SUR4 family. Members of this family play a role in elongation of long chain fatty acids to provide precursors for synthesis of sphingolipids and ceramides.

Source: NCBI Gene 83401 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 46 total
• Druggable target: yes
• MANE Select transcript: NM_152310

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18047
Approved symbol	ELOVL3
Name	ELOVL fatty acid elongase 3
Location	10q24.32
Locus type	gene with protein product
Status	Approved
Aliases	CIG-30
Ensembl gene	ENSG00000119915
Ensembl biotype	protein_coding
OMIM	611815
Entrez	83401

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000370005

RefSeq mRNA: 1 — MANE Select: NM_152310 NM_152310

CCDS: CCDS7531

Canonical transcript exons

ENST00000370005 — 4 exons

Exon	Start	End
ENSE00000811501	102228417	102228568
ENSE00000811502	102227626	102227757
ENSE00001451468	102228825	102229589
ENSE00001451470	102226299	102226649

Expression profiles

Bgee: expression breadth ubiquitous, 141 present calls, max score 96.72.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1580 / max 10.1365, expressed in 72 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106690	0.1580	72

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper leg skin	UBERON:0004262	96.72	gold quality
upper arm skin	UBERON:0004263	91.22	gold quality
mammalian vulva	UBERON:0000997	89.92	gold quality
oocyte	CL:0000023	88.01	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.33	gold quality
secondary oocyte	CL:0000655	79.73	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.39	gold quality
adrenal tissue	UBERON:0018303	72.55	gold quality
skin of abdomen	UBERON:0001416	72.04	gold quality
monocyte	CL:0000576	69.46	gold quality
zone of skin	UBERON:0000014	69.36	gold quality
leukocyte	CL:0000738	68.87	gold quality
skin of leg	UBERON:0001511	66.35	gold quality
right lung	UBERON:0002167	64.60	gold quality
granulocyte	CL:0000094	63.48	gold quality
omental fat pad	UBERON:0010414	62.84	gold quality
peritoneum	UBERON:0002358	62.78	gold quality
right adrenal gland cortex	UBERON:0035827	62.42	gold quality
adipose tissue of abdominal region	UBERON:0007808	62.01	gold quality
adipose tissue	UBERON:0001013	60.64	gold quality
ileal mucosa	UBERON:0000331	59.92	silver quality
nipple	UBERON:0002030	59.35	gold quality
right adrenal gland	UBERON:0001233	59.28	gold quality
subcutaneous adipose tissue	UBERON:0002190	58.76	gold quality
bone marrow cell	CL:0002092	58.47	gold quality
bone marrow	UBERON:0002371	57.61	gold quality
tibialis anterior	UBERON:0001385	56.58	silver quality
upper lobe of left lung	UBERON:0008952	56.42	gold quality
adrenal cortex	UBERON:0001235	56.13	gold quality
left adrenal gland cortex	UBERON:0035825	55.99	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.29

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1H3, PPARA, PPARG, SREBF1

miRNA regulators (miRDB)

32 targeting ELOVL3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-302B-5P	99.50	69.49	1857
HSA-MIR-302D-5P	99.50	69.34	1863
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-532-3P	99.34	65.76	1195
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-382-3P	98.83	67.10	1074
HSA-MIR-6501-3P	98.71	67.45	1480
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-6867-3P	98.12	66.07	1305
HSA-MIR-8089	97.74	66.21	1698

Literature-anchored findings (GeneRIF, showing 2)

• Study found that BRG1 expression was up-regulated along with Elvol3 in prostate cancer cells. BRG1 over-expression dose-dependently augmented the induction of the Elovl3 promoter activity, suggesting that regulation of Elovl3 expression by BRG1 occurred at the transcriptional level. (PMID:31154107)
• Elongation of very long chain fatty acids-3 (Elovl3) is activated by ZHX2 and is a regulator of cell cycle progression. (PMID:37847682)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:92749	ENSDARG00000012632
danio_rerio	elovl6l	ENSDARG00000038639
mus_musculus	Elovl3	ENSMUSG00000038754
rattus_norvegicus	Elovl3	ENSRNOG00000019124
drosophila_melanogaster	Baldspot	FBGN0260960
caenorhabditis_elegans		WBGENE00001241
caenorhabditis_elegans		WBGENE00001242
caenorhabditis_elegans		WBGENE00001247

Paralogs (6): ELOVL5 (ENSG00000012660), ELOVL1 (ENSG00000066322), ELOVL4 (ENSG00000118402), ELOVL7 (ENSG00000164181), ELOVL6 (ENSG00000170522), ELOVL2 (ENSG00000197977)

Protein

Protein identifiers

Very long chain fatty acid elongase 3 — Q9HB03 (reviewed: Q9HB03)

Alternative names: 3-keto acyl-CoA synthase ELOVL3, Cold-inducible glycoprotein of 30 kDa, ELOVL fatty acid elongase 3, Elongation of very long chain fatty acids protein 3, Very long chain 3-ketoacyl-CoA synthase 3, Very long chain 3-oxoacyl-CoA synthase 3

All UniProt accessions (1): Q9HB03

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and unsaturated acyl-CoA substrates with higher activity toward C18 acyl-CoAs, especially C18:0 acyl-CoAs. May participate in the production of saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators.

Subunit / interactions. Interacts with TECR.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Testis.

Post-translational modifications. N-Glycosylated.

Domain organisation. The C-terminal di-lysine motif may confer endoplasmic reticulum localization.

Pathway. Lipid metabolism; polyunsaturated fatty acid biosynthesis.

Similarity. Belongs to the ELO family. ELOVL3 subfamily.

RefSeq proteins (1): NP_689523* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002076	ELO_fam	Family
IPR030457	ELO_CS	Conserved_site
IPR033679	ELOVL3	Family

Pfam: PF01151

Catalyzed reactions (Rhea), 9 shown:

• a very-long-chain acyl-CoA + malonyl-CoA + H(+) = a very-long-chain 3-oxoacyl-CoA + CO2 + CoA (RHEA:32727)
• hexadecanoyl-CoA + malonyl-CoA + H(+) = 3-oxooctadecanoyl-CoA + CO2 + CoA (RHEA:35315)
• octadecanoyl-CoA + malonyl-CoA + H(+) = 3-oxoeicosanoyl-CoA + CO2 + CoA (RHEA:35319)
• eicosanoyl-CoA + malonyl-CoA + H(+) = 3-oxodocosanoyl-CoA + CO2 + CoA (RHEA:35327)
• (9Z,12Z)-octadecadienoyl-CoA + malonyl-CoA + H(+) = (11Z,14Z)-3-oxoicosa-11,14-dienoyl-CoA + CO2 + CoA (RHEA:36503)
• docosanoyl-CoA + malonyl-CoA + H(+) = 3-oxotetracosanoyl-CoA + CO2 + CoA (RHEA:36507)
• (9Z)-octadecenoyl-CoA + malonyl-CoA + H(+) = 3-oxo-(11Z)-eicosenoyl-CoA + CO2 + CoA (RHEA:36511)
• (9Z,12Z,15Z)-octadecatrienoyl-CoA + malonyl-CoA + H(+) = (11Z,14Z,17Z)-3-oxoeicosatrienoyl-CoA + CO2 + CoA (RHEA:36523)
• tetradecanoyl-CoA + malonyl-CoA + H(+) = 3-oxohexadecanoyl-CoA + CO2 + CoA (RHEA:39167)

UniProt features (11 total): transmembrane region 7, glycosylation site 2, chain 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HB03-F1	90.74	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 110, 6

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-2046105	Linoleic acid (LA) metabolism
R-HSA-2046106	alpha-linolenic acid (ALA) metabolism
R-HSA-75876	Synthesis of very long-chain fatty acyl-CoAs
R-HSA-9844594	Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
R-HSA-9933387	RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression

MSigDB gene sets: 140 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, REACTOME_SYNTHESIS_OF_VERY_LONG_CHAIN_FATTY_ACYL_COAS, BENPORATH_ES_WITH_H3K27ME3, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_LONG_CHAIN_FATTY_ACID_METABOLIC_PROCESS, GOBP_NUCLEOSIDE_PHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_ORGANIC_ACID_BIOSYNTHETIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, EVI1_05, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, MARTINEZ_RB1_TARGETS_UP, GOBP_FATTY_ACYL_COA_METABOLIC_PROCESS, GOBP_SULFUR_COMPOUND_BIOSYNTHETIC_PROCESS

GO Biological Process (14): unsaturated fatty acid biosynthetic process (GO:0006636), fatty acid elongation, saturated fatty acid (GO:0019367), sphingolipid biosynthetic process (GO:0030148), fatty acid elongation, monounsaturated fatty acid (GO:0034625), fatty acid elongation, polyunsaturated fatty acid (GO:0034626), long-chain fatty-acyl-CoA biosynthetic process (GO:0035338), alpha-linolenic acid metabolic process (GO:0036109), very long-chain fatty acid biosynthetic process (GO:0042761), linoleic acid metabolic process (GO:0043651), positive regulation of cold-induced thermogenesis (GO:0120162), lipid metabolic process (GO:0006629), fatty acid metabolic process (GO:0006631), fatty acid biosynthetic process (GO:0006633), fatty acid elongation (GO:0030497)

GO Molecular Function (3): fatty acid elongase activity (GO:0009922), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism	2
Fatty acyl-CoA biosynthesis	1
Transcriptional regulation of brown and beige adipocyte differentiation	1
Circadian clock	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
fatty acid biosynthetic process	3
unsaturated fatty acid metabolic process	3
lipid biosynthetic process	2
fatty acid elongation, unsaturated fatty acid	2
long-chain fatty acid metabolic process	2
olefinic compound metabolic process	2
fatty acid elongation	1
sphingolipid metabolic process	1
long-chain fatty-acyl-CoA metabolic process	1
fatty-acyl-CoA biosynthetic process	1
very long-chain fatty acid metabolic process	1
positive regulation of multicellular organismal process	1
cold-induced thermogenesis	1
regulation of cold-induced thermogenesis	1
primary metabolic process	1
lipid metabolic process	1
monocarboxylic acid metabolic process	1
fatty acid metabolic process	1
monocarboxylic acid biosynthetic process	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
binding	1
catalytic activity	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

954 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELOVL3	CIDEA	O60543	809
ELOVL3	UCP1	P25874	794
ELOVL3	AWAT1	Q58HT5	755
ELOVL3	PRDM16	Q9HAZ2	752
ELOVL3	DIO2	Q92813	722
ELOVL3	FABP4	P15090	695
ELOVL3	COX7A1	P24310	694
ELOVL3	DGAT2	Q96PD7	675
ELOVL3	PPARGC1A	Q9UBK2	664
ELOVL3	SCD	O00767	627
ELOVL3	PLIN1	O60240	618
ELOVL3	TMEM26	Q6ZUK4	598
ELOVL3	CPT1B	Q92523	578
ELOVL3	FASN	P49327	577
ELOVL3	ADRB3	P13945	576

IntAct

7 interactions, top by confidence:

A	B	Type	Score
TECR	HACD2	psi-mi:“MI:0914”(association)	0.850
TECR	HACD1	psi-mi:“MI:0914”(association)	0.700
MUC20	ELOVL3	psi-mi:“MI:0915”(physical association)	0.370
ELOVL3	APOB	psi-mi:“MI:0914”(association)	0.350
TECR	HSD17B12	psi-mi:“MI:0914”(association)	0.350

BioGRID (7): ELOVL3 (Synthetic Lethality), STOM (Affinity Capture-MS), APOB (Affinity Capture-MS), ACTA1 (Affinity Capture-MS), ATP13A3 (Affinity Capture-MS), ELOVL3 (Affinity Capture-Western), MUC20 (Two-hybrid)

ESM2 similar proteins: A0A0C5PHQ7, A0JNC4, A1L3X0, B4QVX4, D4A612, D4ADY9, G5EEE5, O35949, P49191, Q03574, Q1A3B0, Q1HRV8, Q20300, Q20303, Q2KJD9, Q32NI8, Q3S8M4, Q4D321, Q4D5J7, Q4DHY3, Q4DUK4, Q4QJ85, Q4R516, Q54TC9, Q57UP6, Q57X51, Q5M8U1, Q5RFL5, Q6GLX2, Q6P4N1, Q6PC64, Q84QC0, Q8BHI7, Q8IU89, Q920L5, Q920L6, Q920L7, Q95K73, Q9BW60, Q9D2Y9

Diamond homologs: A1L3X0, D4ADY9, G5EEE5, P49191, Q03574, Q20300, Q20303, Q4D5J7, Q4DHY2, Q4DUK4, Q4DUK7, Q4Q5G6, Q4QJ85, Q555E8, Q57UP7, Q57UP8, Q5ZJR8, Q6PC64, Q7LKX0, Q86JM5, Q920L5, Q920L6, Q9D2Y9, Q9H5J4, Q9HB03, Q9VH58, Q9VV87, Q9XVQ9, A0A0C5PHQ7, A0JNC4, O35949, Q2KJD9, Q4DHY3, Q4R516, Q54CJ4, Q57UP6, Q5RFL5, Q8BHI7, Q920L7, Q9BW60

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ELOVL3	“down-regulates quantity”	palmitoyl-CoA	“chemical modification”
ELOVL3	“up-regulates quantity”	3-hydroxyoctadecanoyl-CoA	“chemical modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

46 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

876 predictions. Top by Δscore:

Variant	Effect	Δscore
10:102226621:GACA:G	donor_gain	1.0000
10:102227113:G:GT	donor_gain	1.0000
10:102227754:TCAGG:T	donor_loss	1.0000
10:102227755:CAGG:C	donor_loss	1.0000
10:102227756:AGGTA:A	donor_loss	1.0000
10:102227757:GGTAA:G	donor_loss	1.0000
10:102227759:T:G	donor_loss	1.0000
10:102228415:A:AG	acceptor_gain	1.0000
10:102228416:G:GA	acceptor_gain	1.0000
10:102228416:GT:G	acceptor_gain	1.0000
10:102226576:G:GT	donor_gain	0.9900
10:102226641:G:GT	donor_gain	0.9900
10:102226642:GAGTA:G	donor_gain	0.9900
10:102226647:TTGG:T	donor_loss	0.9900
10:102226648:TGGTG:T	donor_loss	0.9900
10:102226649:GGTG:G	donor_loss	0.9900
10:102226650:G:A	donor_loss	0.9900
10:102226651:T:G	donor_loss	0.9900
10:102227616:T:TA	acceptor_gain	0.9900
10:102227621:GCCAG:G	acceptor_loss	0.9900
10:102227622:CCA:C	acceptor_loss	0.9900
10:102227624:AG:A	acceptor_gain	0.9900
10:102227625:G:GT	acceptor_loss	0.9900
10:102227625:GG:G	acceptor_gain	0.9900
10:102227673:T:TA	acceptor_gain	0.9900
10:102227758:G:GG	donor_gain	0.9900
10:102228413:TCA:T	acceptor_loss	0.9900
10:102228414:CAG:C	acceptor_loss	0.9900
10:102228416:G:GT	acceptor_loss	0.9900
10:102228416:GTAT:G	acceptor_gain	0.9900

AlphaMissense

1807 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:102229187:T:C	F250L	0.997
10:102229189:T:A	F250L	0.997
10:102229189:T:G	F250L	0.997
10:102228881:C:G	H148D	0.996
10:102228961:C:A	N174K	0.996
10:102228961:C:G	N174K	0.996
10:102228555:G:C	K124N	0.994
10:102228555:G:T	K124N	0.994
10:102228887:A:C	S150R	0.994
10:102228889:C:A	S150R	0.994
10:102228889:C:G	S150R	0.994
10:102228828:A:C	D130A	0.993
10:102228944:T:A	W169R	0.993
10:102228944:T:C	W169R	0.993
10:102227756:A:C	S78R	0.992
10:102228417:T:A	S78R	0.992
10:102228417:T:G	S78R	0.992
10:102228550:A:C	S123R	0.992
10:102228552:C:A	S123R	0.992
10:102228552:C:G	S123R	0.992
10:102228828:A:T	D130V	0.992
10:102228884:C:G	H149D	0.992
10:102228831:C:T	T131I	0.991
10:102228886:C:A	H149Q	0.991
10:102228886:C:G	H149Q	0.991
10:102228827:G:C	D130H	0.990
10:102228529:T:A	W116R	0.989
10:102228529:T:C	W116R	0.989
10:102228828:A:G	D130G	0.989
10:102228878:T:G	Y147D	0.989

dbSNP variants (sampled 300 via entrez): RS1000237780 (10:102225940 G>C,T), RS1001237297 (10:102224638 C>T), RS1001335132 (10:102226167 A>G), RS1002125245 (10:102223420 A>G), RS1002234427 (10:102226739 C>T), RS1003132174 (10:102228140 C>G,T), RS1004075703 (10:102223510 A>G), RS1005140000 (10:102228813 T>C), RS1005654010 (10:102225086 C>T), RS1005773081 (10:102224721 G>C), RS1006142399 (10:102227140 C>T), RS1006527861 (10:102222935 A>C), RS1007147284 (10:102225410 T>C), RS1007414787 (10:102223889 C>T), RS1008559961 (10:102224179 G>A,C)

Disease associations

OMIM: gene MIM:611815 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST005141_71	Cognitive ability (MTAG)	3.000000e-13
GCST005142_30	Cognitive ability	3.000000e-06
GCST005316_72	Intelligence (MTAG)	6.000000e-19
GCST005956_50	Waist-to-hip ratio adjusted for BMI	8.000000e-06
GCST005958_15	Waist-to-hip ratio adjusted for BMI (age >50)	4.000000e-06
GCST005962_36	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	6.000000e-07
GCST006269_517	General cognitive ability	8.000000e-15
GCST010002_298	Refractive error	3.000000e-22
GCST011703_47	Smoking initiation	2.000000e-10

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004337	intelligence
EFO:0004784	self reported educational attainment
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0005670	smoking initiation

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5791 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

9 potent at pChembl≥5 of 9 total, top 9 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.23	IC50	59	nM	CHEMBL493642
6.89	IC50	130	nM	CHEMBL570571
6.66	IC50	221	nM	CHEMBL490750
6.47	IC50	337	nM	CHEMBL449121
6.43	IC50	375	nM	CHEMBL490110
6.30	IC50	503	nM	CHEMBL491944
5.96	IC50	1100	nM	CHEMBL491949
5.82	IC50	1510	nM	CHEMBL574934
5.16	IC50	6940	nM	CHEMBL2308139

PubChem BioAssay actives

9 with measured affinity, of 10 total; 9 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6,6-dimethyl-3-[5-methyl-3-oxo-2-(4-propan-2-ylphenyl)-1H-pyrazol-4-yl]-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione	350116: Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	ic50	0.0590	uM
4-fluoro-N-[[(4S)-2-oxo-6-(1H-pyrazol-5-yl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-4-yl]methyl]benzamide	441682: Inhibition of human ELOVL3	ic50	0.1300	uM
3-[2-(4-chlorophenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione	350116: Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	ic50	0.2210	uM
6,6-dimethyl-3-[5-methyl-3-oxo-2-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-4-yl]-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione	350116: Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	ic50	0.3370	uM
6,6-dimethyl-3-[5-methyl-2-(4-methylphenyl)-3-oxo-1H-pyrazol-4-yl]-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione	350116: Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	ic50	0.3750	uM
3-[2-(4-methoxyphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]-6,6-dimethyl-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindole-2,4-dione	350116: Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	ic50	0.5030	uM
4-[4-[6,6-dimethyl-2,4-dioxo-1-phenyl-3-(trifluoromethyl)-5,7-dihydroindol-3-yl]-5-methyl-3-oxo-1H-pyrazol-2-yl]benzonitrile	350116: Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	ic50	1.1000	uM
2-(1-methylimidazol-4-yl)sulfonyl-N-(4-propan-2-yloxyphenyl)-2-azabicyclo[2.2.2]octane-6-carboxamide	437051: Inhibition of C-terminal V5-epitope-tagged human ELOVL3 expressed in african green monkey COS7 cells	ic50	1.5100	uM
(1R,5S)-3-pyridin-2-ylsulfonyl-N-[4-(trifluoromethyl)phenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide	420896: Inhibition of human ELOVL3 expressed in Pichia pastoris SND1168	ic50	6.9400	uM

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases methylation, affects methylation, increases expression	3
Valproic Acid	increases expression	3
aristolochic acid I	increases expression	1
methylmercuric chloride	increases expression, decreases response to substance	1
propionaldehyde	increases expression	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases methylation	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
butyraldehyde	increases expression	1
linalool	decreases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
nutlin 3	affects cotreatment, increases expression	1
quinocetone	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Aldehydes	increases expression	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Endosulfan	decreases expression	1
Mercuric Chloride	decreases response to substance, increases expression	1
Nickel	decreases expression	1
Phthalic Acids	increases methylation	1
Quercetin	increases expression	1
Silicon Dioxide	decreases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Thiram	decreases expression	1
Urethane	increases expression	1
Lactic Acid	decreases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1007917	Binding	Inhibition of human ELOVL3 expressed in african green monkey COS7 cells assessed as stearoyl-CoA elongation	Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.